3D-printed molds to guide tissue sampling from removed tumors in people with cancer
Tests 3D-printed molds that guide where tissue is sampled from removed tumors.
Plain-language title generated from the registry record
Registry title: Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial
Key facts
- Where
- Tampere, FinlandSee the site
Where in Finland
- Tampere University HospitalTampere, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tampere University Hospital
- Trial code
- NCT07778173
- Record updated
- 21 August 2026
- Original description
Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.Read full original descriptionShow less
Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial
Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.
Inclusion: To be eligible for the study, the study candidate must:; be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (<15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s)); have a malignant or likely malignant tumor/tumors and undergo a surgical operation.
Exclusion: To be eligible for the study, the study candidate cannot:; lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (<15-year-old), the child is not eligible); be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.